Thursday, July 31, 2014
undisclosed company has picked up an integrin-targeting antibody from the University of California, San Francisco that could address
the underlying pathology in chronic obstructive pulmonary disease by improving
airway remodeling via suppressing transforming
The home run will be whether the antibody reverses existing damage.
Homing in on
first step toward finding a site to attack on integrin b8 was to look at its
conformation in the context of the natural integrin avb8 dimer. Using chromatography and electron microscopy, the team found
that unlike other integrins, integrin b8 exists on the
surface of cultured cells in a constitutively active form.
demonstrated that the integrin b8 mAb can prevent
airway deterioration, the key question is whether it can improve established
The fibrotic mechanisms at the root of COPD are similar
to the ones that cause idiopathic pulmonary fibrosis (IPF), with aberrant TGFB1
activation by integrin complexes governing both processes. For example, integrin αvb6
has been highlighted as a key player in IPF.
Boettner, B. SciBX 7(29); doi:10.1038/scibx.2014.848
Published online July 31, 2014
1. Minagawa, S. et al.
Sci. Transl. Med.; published online June 18, 2014;
Contact: Stephen L. Nishimura, University of California,
San Francisco, Calif.
2. Wilkinson, T.M.A. et
al. Am. J. Respir. Crit. Care Med. 173, 871-876 (2006)
3. Kitamura, H. et al.
J. Clin. Invest. 121, 2863-2875 (2011)
4. Mu, D. et al. J.
Cell Biol. 157, 493-507 (2002)
5. Chilosi, M. et al.
Respir. Res. 13, 3 (2012)
(NASDAQ:AMGN), Thousand Oaks, Calif.
Antegrin Therapeutics LLC, St. Louis, Mo.
Biogen Idec Inc.
(NASDAQ:BIIB), Weston, Mass.
Center for World Health & Medicine at Saint Louis
University, St. Louis, Mo.
Regents of the University of California, Oakland, Calif.
Saint Louis University School of Medicine, St. Louis, Mo.
University of California, San Francisco, Calif.
VeritasRx Consulting, Meridian, Idaho